Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) Research & Development (2021 - 2025)

Historic Research & Development for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to $287000.0.

  • Journey Medical's Research & Development fell 6591.45% to $287000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $544000.0, marking a year-over-year decrease of 9511.84%. This contributed to the annual value of $9.9 million for FY2024, which is 3071.21% up from last year.
  • Per Journey Medical's latest filing, its Research & Development stood at $287000.0 for Q3 2025, which was down 6591.45% from $39000.0 recorded in Q1 2025.
  • Over the past 5 years, Journey Medical's Research & Development peaked at $7.9 million during Q1 2024, and registered a low of $29000.0 during Q2 2021.
  • Its 5-year average for Research & Development is $1.8 million, with a median of $1.5 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 889655.17% in 2022, then plummeted by 9950.53% in 2025.
  • Journey Medical's Research & Development (Quarter) stood at $2.0 million in 2021, then skyrocketed by 113.65% to $4.3 million in 2022, then plummeted by 64.64% to $1.5 million in 2023, then plummeted by 85.51% to $218000.0 in 2024, then surged by 31.65% to $287000.0 in 2025.
  • Its Research & Development stands at $287000.0 for Q3 2025, versus $39000.0 for Q1 2025 and $218000.0 for Q4 2024.